Esperion Therapeutics’ (ESPR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report published on Thursday,Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also commented on ESPR. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. Cantor Fitzgerald started coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.25.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $2.08 on Thursday. Esperion Therapeutics has a 1-year low of $1.58 and a 1-year high of $3.94. The firm has a market capitalization of $409.84 million, a P/E ratio of -3.25 and a beta of 1.03. The business’s 50-day simple moving average is $2.46 and its 200-day simple moving average is $2.18.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The business had revenue of $51.63 million for the quarter, compared to analysts’ expectations of $55.44 million. During the same quarter last year, the business posted ($0.37) earnings per share. On average, equities research analysts expect that Esperion Therapeutics will post -0.28 EPS for the current fiscal year.

Institutional Trading of Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Traphagen Investment Advisors LLC acquired a new position in Esperion Therapeutics during the 3rd quarter worth $27,000. Xponance Inc. bought a new position in shares of Esperion Therapeutics during the second quarter worth about $28,000. Versor Investments LP acquired a new position in Esperion Therapeutics in the third quarter worth about $44,000. American Century Companies Inc. bought a new stake in Esperion Therapeutics in the second quarter valued at about $50,000. Finally, SJS Investment Consulting Inc. acquired a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $55,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.